ONO-4578 is an investigational medication being studied for the treatment of colorectal cancer. It is being tested in combination with other medications as a first-line treatment for specific types of advanced colorectal cancer.

Opdivo (nivolumab) is an immunotherapy medication that helps the body’s immune system attack cancer cells. It works by blocking a protein that prevents the immune system from attacking cancer cells.

mFOLFOX6 is a combination chemotherapy regimen that includes several medications working together to fight cancer cells. It is commonly used as a standard treatment for colorectal cancer.

Bevacizumab is a targeted therapy that works by blocking the formation of new blood vessels that feed tumors. This helps prevent tumor growth by cutting off their blood supply.

PD-L1 Positive Advanced Colorectal Cancer – A type of bowel cancer that has spread beyond its original location and shows specific protein markers called PD-L1 on the surface of cancer cells. The disease begins in the large intestine (colon) or rectum and develops from small growths called polyps that become cancerous over time. As it advances, the cancer grows through the layers of the intestinal wall and can spread to nearby lymph nodes and other organs. The presence of PD-L1 proteins on cancer cells makes this particular type distinct from other forms of colorectal cancer. The disease typically develops gradually, often starting with no symptoms and progressing to changes in bowel habits, abdominal discomfort, and unexplained weight loss.